STURDYNCT05704036
Estrogen Supplementation and Bone Health in Women With CF
At risk: Primary completion moved at least 11 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Jan 2027 to Jan 2028
- Eligibility criteria expanded, about 23 words
- Study completion pushed from Jan 2027 to Jan 2029
- Secondary endpoints: details revised at 3 of 3 entries
- Notable Primary and study completion dates: Dec 2025 to Jan 2027v8
- Minor Site contact updatedv7
Notable Primary and study completion dates: Dec 2024 to Dec 2025v6 Show 5 more changesShow less
- Eligibility criteria expanded, about 58 words
- Primary endpoints: 4 to 1
- Interventions: Placebo patch (Drug), Placebo pill (Drug), Progesterone (Drug), Transdermal estrogen (Drug) to Progesterone (Drug), Transdermal estrogen (Drug)
- Secondary endpoints: 5 to 3
- Study title shortened, about 2 words
- Minor Start date changed from estimate of Jun 2023 to May 2, 2023v5
Show 3 earlier versionsHide 3 earlier versions
- Notable Start date: Apr 2023 to Jun 2023v4
- Minor Start date: Mar 2023 to Apr 2023v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Jan 2023 to Mar 2023
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change in lumbar spine bone mineral density assessed by dual-energy x-ray absorptiometry (DXA)
Timeframe: Baseline and 12 months
Secondary (3)
Change in serum procollagen type I intact N-terminal propeptide (P1NP) levels (mcg/L)
Change in serum C-terminal telopeptide of type I collagen (CTX-1) levels (pg/mL)
Change in quality of life as assessed by Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score (CFRSD-CRISS) questionnaire
Arms and interventions
Observational StudyNo intervention
Participants will complete three study visits (baseline, 6 months, and 12 months) involving DXAs (bone density assessment), x-rays, blood draws, and questionnaires.
Transdermal Estradiol/Cyclic ProgesteroneExperimental
Participants will apply transdermal estradiol patches (0.1 mg/day) weekly for 12 months following baseline study visits. Participants not already using a progesterone-containing contraceptive will also take progesterone (200 mg) for 10 days per month.
Drugs: Transdermal estrogen, Progesterone
Sites
1 site in 1 country
- Johns HopkinsBaltimore, Maryland, United States